Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
1999-07-07
2002-07-02
Wilson, James O. (Department: 1623)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
Reexamination Certificate
active
06414135
ABSTRACT:
FIELD OF THE INVENTION
The present invention is directed to C3′-methylene hydrogen phosphonate monomers, oligonucleotides containing such methylene hydrogen phosphonate monomers, and methods for the preparation of such monomers and oligonucleotides.
BACKGROUND OF THE INVENTION
It is well known that most of the bodily states in mammals, including most disease states, are effected by proteins. Proteins, either acting directly or through their enzymatic functions, contribute in major proportion to many diseases in animals and man.
Classical therapeutics generally has focused upon interactions with proteins in an effort to moderate their disease-causing or disease-potentiating functions. Recently, however, attempts have been made to moderate the production of proteins by interactions with the molecules (i.e., intracellular RNA) that direct their synthesis. These interactions have involved hybridization of complementary “antisense” oligonucleotides or certain analogs thereof to RNA. Hybridization is the sequence-specific hydrogen bonding of oligonucleotides or oligonucleotide analogs to RNA or to single stranded DNA. By interfering with the production of proteins, it has been hoped to effect therapeutic results with maximum effect and minimal side effects.
Oligonucleotides and their analogs have been developed and used in molecular biology in a variety of procedures as probes, primers, linkers, adapters, and gene fragments. The pharmacological activity of antisense oligonucleotides and oligonucleotide analogs, like other therapeutics, depends on a number of factors that influence the effective concentration of these agents at specific intracellular targets. One important factor for oligonucleotides is the stability of the species in the presence of nucleases. It is unlikely that unmodified oligonucleotides will be useful therapeutic agents because they are rapidly degraded by nucleases. Modification of oligonucleotides to render them resistant to nucleases therefore is greatly desired.
Modification of oligonucleotides to enhance nuclease resistance generally has taken place on the phosphorus atom of the sugar-phosphate backbone. Examples of such modifications include methyl phosphonate, phosphorothioate, phosphorodithioate, phosphoramidate and phosphotriester linkages, and 2′-O-methyl ribose sugar units. Phosphate-modified oligonucleotides, however, generally have suffered from inferior hybridization properties. See, e.g., Cohen, J. S., ed. Oligonucleotides:
Antisense Inhibitors of Gene Expression,
(CRC Press, Inc., Boca Raton, Fla., 1989). Other modifications to oligonucleotides include labeling with nonisotopic labels, e.g. fluorescein, biotin, digoxigenin, alkaline phosphatase, or other reporter molecules.
Another key factor is the ability of antisense compounds to traverse the plasma membrane of specific cells involved in the disease process. Cellular membranes consist of lipid-protein bilayers that are freely permeable to small, nonionic, lipophilic compounds and are inherently impermeable to most natural metabolites and therapeutic agents. See, e.g., Wilson,
Ann. Rev. Biochem.
1978, 47, 933. The biological and antiviral effects of natural and modified oligonucleotides in cultured mammalian cells have been well documented. It appears that these agents can penetrate membranes to reach their intracellular targets. Uptake of antisense compounds into a variety of mammalian cells, including HL-60, Syrian Hamster fibroblast, U937, L929, CV-1 and ATH8 cells has been studied using natural oligonucleotides and certain nuclease resistant analogs, such as alkyl triesters and methyl phosphonates. See, e.g., Miller et al.,
Biochemistry
1977, 16, 1988; Marcus-Sekura et al.,
Nuc. Acids Res.
1987, 15, 5749; and Loke et al.,
Top. Microbiol. Immunol.
1988, 141, 282.
Often, modified oligonucleotides and oligonucleotide analogs are internalized less readily than their natural counterparts. As a result, the activity of many previously available antisense oligonucleotides has not been sufficient for practical therapeutic, research or diagnostic purposes. Two other serious deficiencies of prior art compounds designed for antisense therapeutics are inferior hybridization to intracellular RNA and the lack of a defined chemical or enzyme-mediated event to terminate essential RNA functions.
Modifications to enhance the effectiveness of the antisense oligonucleotides and overcome these problems have taken many forms. These modifications include base ring modifications, sugar moiety modifications and sugar-phosphate backbone modifications. Prior sugar-phosphate backbone modifications, particularly on the phosphorus atom, have effected various levels of resistance to nucleases. However, while the ability of an antisense oligonucleotide to bind to specific DNA or RNA with fidelity is fundamental to antisense methodology, modified phosphorus oligonucleotides have generally suffered from inferior hybridization properties.
Replacement of the phosphorus atom has been an alternative approach in attempting to avoid the problems associated with modification on the pro-chiral phosphate moiety. For example, Matteucci,
Tetrahedron Letters
1990, 31, 2385 discloses the replacement of the phosphorus atom with a methylene group. However, this replacement yielded unstable compounds with nonuniform insertion of formacetal linkages throughout their backbones. Cormier et al.,
Nucleic Acids Research
1988, 16, 4583, discloses replacement of phosphorus with a diisopropylsilyl moiety to yield homopolymers having poor solubility and hybridization properties. Stirchak et al.,
Journal of Organic Chemistry
1987, 52, 4202 discloses replacement of phosphorus linkages by short homopolymers containing carbamate or morpholino linkages to yield compounds having poor solubility and hybridization properties. Mazur et al.,
Tetrahedron
1984, 40, 3949, discloses replacement of a phosphorus linkage with a phosphonic linkage yielding a homotrimer. Goodchild,
Bioconjugate Chemistry
1990, 1, 165, discloses ester linkages that are enzymatically degraded by esterases and, therefore, are not suitable for antisense applications.
Phosphonates are known in the literature but very few 3′-hydrogen phosphonates of nucleosides are known. Synthesis and use of 3′-methylene phosphonic acids and their esters as isosteres of nucleoside-3′-phosphates and phosphodiesters have been reported. Albrecht et al.,
Tetrahedron,
1984, 40, 79; Jones et al.,
J. Am. Chem. Soc.,
1970, 5510; Albrecht et al.,
J. Am. Chem. Soc.,
1970, 5511. All of these phosphonic acids and phosphonates bear 2′-hydroxy groups. Related 2′-hydroxy-3′-phosphonate analogs of nucleoside phosphates have been synthesized through a multistep synthetic procedure. Morr et al.,
Z. Naturforsch.,
1983, 38b, 1665; Morr and Ernst,
Liebigs Ann. Chemie,
1993, 1205. 2′-Deoxy-thymidine-3′-methylene-hydrogen phosphonates have also been reported in WO97/32887 (Sep. 12, 1997).
Thus far only thymidine-3′-methylene hydrogen phosphonates have been reported. Furthermore, these phosphonates bear t-butyldiphenylsilyl protecting groups on the 5′-position which makes use of such phosphonates in conventional oligonucleotide synthesis cumbersome. There exists a need to provide isosteric 3′-methylene hydrogen phosphonate nucleosides that can bear a variety of substitutents at the 2′- and 5′-positions.
Phosphonates have been investigated because of their isosteric relationship with the natural phosphodiester linkage of oligonucleotides. Methyl phosphonates, in which one of the non-nucleosidic oxygen atoms of the natural phospodiester linkage is replaced with a methyl group, have been studied widely. Related isosteres, where either the 3′- or the 5′-oxygen atom of the phosphodiester linkage is replaced with a methylene group, have also been investigated. Mazur et al. have reported the synthesis of a 3′-methylenephosphonate isostere of UpUpU (
Tetrahedron,
1984, 40, 3949). This oligonucleotide
An Haoyun
Cook Phillip Dan
Manoharan Muthiah
Wang Tingmin
ISIS Pharmaceuticals Inc.
Wilson James O.
Woodcock & Washburn LLP
LandOfFree
C3′-methylene hydrogen phosphonate monomers and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with C3′-methylene hydrogen phosphonate monomers and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and C3′-methylene hydrogen phosphonate monomers and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2896575